ImmunityBio, Inc. (IBRX) Total Return Calculator with Dividends Reinvested

ImmunityBio, Inc.

Popular:

The total return for ImmunityBio, Inc. (IBRX) stock is +159.15% over the past 12 months. So far it's up 264.36% this year. The 5-year total return is -45.12%, meaning $10,000 invested in IBRX stock 5 years ago would be worth $5,488 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in IBRX 1 year ago, it would be worth $26,667 today — you'd have gained $16,667.

With Dividends Reinvested$26,667+166.67%

Price Only (No DRIP)$26,667+166.67%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in IBRX

1Y$25,915+$15,915 (+159.2%)159.2% CAGR

3Y$25,915+$15,915 (+159.2%)37.4% CAGR

5Y$5,488-$4,512 (-45.1%)-11.3% CAGR

10Y$11,306+$1,306 (+13.1%)1.2% CAGR

15Y$2,125-$7,875 (-78.8%)-9.8% CAGR

20Y$2,125-$7,875 (-78.8%)-7.5% CAGR

30Y$2,125-$7,875 (-78.8%)-5.0% CAGR

ImmunityBio, Inc. did not pay dividends during this period. Total return = price return.

Loading IBRX total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+264.36%	—	+264.36%	—	$36,436
1Y	+159.15%	159.15%	+159.15%	—	$25,915
3Y	+159.15%	37.36%	+159.15%	—	$25,915
5Y	-45.12%	-11.31%	-45.12%	—	$5,488
10Y	+13.06%	1.23%	+13.06%	—	$11,306
15Y	-78.75%	-9.81%	-78.75%	—	$2,125
20Y	-78.75%	-7.45%	-78.75%	—	$2,125
30Y	-78.75%	-5.03%	-78.75%	—	$2,125

Risk & Highlights

Best Year+236.62%2020

Worst Year-73.52%2018

Max Drawdown-42.34%2026-02-24 → 2026-03-30

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+384.16%	+384.16%	—	+0.41%	+383.7pp
2025	-22.96%	-22.96%	—	+16.64%	-39.6pp
2024	-51.14%	-51.14%	—	+24.00%	-75.1pp
2023	+5.24%	+5.24%	—	+24.81%	-19.6pp
2022	-32.67%	-32.67%	—	-19.95%	-12.7pp

IBRX outperformed the S&P 500 by 134.16pp over the past year (+159.15% vs +24.99%).

Loading summary...

IBRX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
IBRXImmunityBio, Inc.	$7.7B	-8.0%	+264.4%	+159.2%	—	+159.2%	-45.1%	+13.1%
NKTRNektar Therapeutics	$1.2B	-10.9%	+40.4%	+608.2%	—	+639.2%	-76.1%	-73.3%
FATEFate Therapeutics, Inc.	$244M	+20.8%	+111.1%	+72.7%	—	-64.4%	-97.4%	+4.5%
CRISCuris, Inc.	$82M	-12.3%	-57.0%	-81.7%	—	-97.5%	-99.7%	-99.7%
ADCTADC Therapeutics S.A.	$139M	-65.6%	-69.0%	-64.0%	—	-52.2%	-95.3%	-96.3%
IMVTImmunovant, Inc.	$7.3B	+33.2%	+36.4%	+122.8%	—	+77.8%	+214.7%	+255.2%
RCUSArcus Biosciences, Inc.	$2.4B	+3.9%	+4.4%	+185.7%	—	+28.3%	+5.4%	+43.0%
NKGNNKGen Biotech, Inc. Common Stock	$3M	+0.0%	+20.0%	-75.0%	—	-98.9%	-98.9%	-98.9%
AGENAgenus Inc.	$125M	-5.1%	-7.1%	-32.9%	—	-92.0%	-97.1%	-96.4%
CLDXCelldex Therapeutics, Inc.	$2.2B	+7.3%	+20.1%	+55.8%	—	-11.9%	+16.7%	-51.0%
HALOHalozyme Therapeutics, Inc.	$8.1B	+1.6%	-2.5%	+29.0%	—	+98.3%	+65.5%	+688.4%

Compare:IBRX vs NKTR IBRX vs FATE IBRX vs CRIS IBRX vs NKTR vs FATE

About IBRX Dividend Returns

ImmunityBio, Inc. (IBRX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of IBRX over the past year?

ImmunityBio, Inc. (IBRX) delivered a return of 159.15% over the past year. Since IBRX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in IBRX be worth today?

A $10,000 investment in ImmunityBio, Inc. one year ago would be worth $25,915 today, representing a gain of $15,915.

Q3Does IBRX pay dividends?

ImmunityBio, Inc. (IBRX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For IBRX, the total return equals the price-only return.

Q4Did IBRX beat the S&P 500?

Yes, ImmunityBio, Inc. (IBRX) outperformed the S&P 500 by 134.16 percentage points over the past year. IBRX delivered a total return of 159.15%, compared to the S&P 500's 24.99%. This 134.16pp alpha means investors in IBRX earned more than a passive S&P 500 index fund.

Q5What is IBRX's worst drawdown?

ImmunityBio, Inc. (IBRX) experienced a maximum drawdown of -42.34% over the past year, declining from its peak on 2026-02-24 to its trough on 2026-03-30. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is IBRX's long-term total return over 10, 20, or 30 years?

Here are ImmunityBio, Inc. (IBRX)'s long-term returns with dividends reinvested. Over 10 years, the total return is 13.1% (1.2% CAGR) — $10,000 would have grown to $11,306. Over 20 years: -78.8% total return (-7.5% CAGR) — $10,000 → $2,125. Over 30 years: -78.8% total return (-5.0% CAGR) — $10,000 → $2,125. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was IBRX's best and worst year?

ImmunityBio, Inc.'s best calendar year was 2020 with a total return of 236.6%. Its worst year was 2018 with a total return of -73.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 310.1 percentage points.

How much would $100/month in IBRX be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →